Denosumab an emerging treatment for postmenopausal osteoporosis

Expert Opinion on Biological Therapy

Volumn 10, Issue 3, 2010, Pages 467-476

  Lewiecki, E Michael ^a  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

Denosumab; OPG; Osteoporosis; RANK; RANKL; Treatment

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; ANTIBIOTIC AGENT; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; IBANDRONIC ACID; LASOFOXIFENE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; TRANSCRIPTION FACTOR PAX5; VITAMIN D; ZOLEDRONIC ACID;

ALBUMIN BLOOD LEVEL; BONE DENSITY; BONE MASS; BONE TURNOVER; BREAST CANCER; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CELLULITIS; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; ESTROGEN THERAPY; FRACTURE; FRACTURE NONUNION; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HYPOCALCEMIA; INFECTION; INJECTION SITE REACTION; JAW OSTEONECROSIS; LEG CRAMP; LUMBAR SPINE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; PROTEIN URINE LEVEL; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; STROKE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VERTEBRA DISLOCATION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; RANK LIGAND;

EID: 76949085453     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712591003604708     Document Type: Review

References (68)

1. Klibanski A, Adams-Campbell L, Bassford T, et al. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785-795
2. Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2(6):285-289
3. European Foundation for Osteoporosis and Bone Disease National Osteoporosis Foundation. Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 1997;7(1):1-6
4. Melton LJ III, Chrischilles EA, Cooper C, et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7(9):1005-1010
5. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353(9156):878-882
6. Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med 1997;103(2A):12S-9S
7. World Health Organisation. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series. Geneva, Switzerland, WHO; 1994. p. 1-129
8. Baim S, Binkley N, Bilezikian JP, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008;11(1):75-91
9. World Health Organization. FRAX WHO Fracture Risk Assessment Tool. 2009. Available from: http://www.shef.ac.uk/ FRAX/ [Last accessed 11 January 2010]
10. Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report (2007). World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK: Printed by the University of Sheffield
11. Wainwright SA, Marshall LM, Ensrud KE, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005;90(5):2787-2793
12. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation. Washington, DC; 2008
13. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19(4):399-428
14. Fujiwara S, Nakamura T, Orimo H, et al. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 2008;19(4):429-435
15. Siminoski K, Leslie WD, Frame H, et al. Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom 2007;10(2):120-123
16. Curtis JR, Carbone L, Cheng H, et al. Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005. J Bone Miner Res 2008;23(7):1061-1067
17. Foley KA, Foster SA, Meadows ES, et al. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. Med Care 2007;45(9):902-906
18. Mccombs JS, Thiebaud P, Laughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48(3):271-287
19. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14(12):965-968
20. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15(12):1003-1008
21. US Department of Health and Human Services. Bone Health and Osteoporosis: a Report of the Surgeon General. US Department of Health and Human Services, Office of the Surgeon General, Rockville, MD, 2004
22. Lewiecki EM. RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 2006;6(10):1041-1050
23. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333
24. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291(14):1701-1712
25. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-1443
26. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-1541
27. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures-Results from the fracture intervention trial. JAMA 1998;280(24):2077-2082
28. Mcclung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-340
29. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91
30. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282(14):1344-1352
31. Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19(8):1241-1249
32. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-1822
33. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357(18):1799-1809
34. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109(4):267-276
35. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90(5):2816-2822
36. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350(5):459-468
37. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene-Results from a 3-year randomized clinical trial. JAMA 1999;282(7):637-645
38. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23(12):1923-1934
39. Cummings SR, Eastell R, Ensrud K, et al. The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial. J Bone Miner Res 2008;23(Suppl 1):S81
40. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-1441
41. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1 - 84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146(5):326-339
42. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Man Care 1998;4:1377-1382
43. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004;19(7):1059-1066
44. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004;93(11):2645-2668
45. Tang L, Persky AM, Hochhaus G, et al. Pharmacokinetic aspects of biotechnology products. J Pharm Sci 2004;93(9):2184-2204
46. Mcclung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354(8):821-831
47. Lewiecki EM, Miller PD, Mcclung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res 2007;22:1832-1841
48. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 2008;43(2):222-229
49. Gallagher JC, Rapuri PB, Haynatzki G, et al. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 2002;87(11):4914-4923
50. Miller P, Bolognese M, Lewiecki E, et al. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 6 year results of a phase 2 clinical trial. 2009. Available from: http://www. asbmr.org/Meetings/ AnnualMeeting/ AbstractDetail.aspx?aid=1cf516b5-29be- 4edf-b1ed-7fa92b4f2031 [Last accessed 11 January 2010]
51. Cummings SR, San Martin J, Mcclung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8):756-765
52. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93(6):2149-2157
53. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24(1):153-161
54. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2009: published online 13 July 2009, doi:10.1359/jbmr.090716
55. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005;208:207-227
56. Xing L, Schwarz EM, Boyce BF. Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev 2005;208:19-29
57. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13(18):2412-2424
58. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397(6717):315-323
59. Stolina M, Dwyer D, Ominsky MS, et al. Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J Immunol 2007;179(11):7497-7505
60. Stolina M, Dwyer D, Morony S, et al. Rats and mice overexpressing soluble OPG have high bone mass but no alteration in immunological parameters or lymphocyte function. Arthritis Rheum 2005;20:S708
61. Reid I, Benhamou CL, Bolognese M, et al. Effects of denosumab on bone histology and histomorphometry: the FREEDOM and STAND studies. 2009. Available from: http://www.asbmr.org/Meetings/ AnnualMeeting/AbstractDetail.aspx? aid=1778e37e-cc4c-482c-a20d- 6ae66570d65d [Last accessed 11 January 2010]
62. Briefing Information for the August 13, 2009 Meeting of the Reproductive Health Drugs Advisory Committee. Washington, DC: United States Food And Drug Administration, Amgen Inc.2009. Available from: http://www.fda.gov/ AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ ReproductiveHealthDrugsAdvisory Committee/ucm176584.htm [Last accessed 11 January 2010]
63. Anastasilakis AD, Toulis KA, Goulis DG, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 2009;41(10):721-729
64. Toulis A, Anastasilakis D. Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab. Osteoporos Int 2009: published online15 December 2009, doi:10.1007/s00198-009-1145-1
65. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26(30):4875-4882
66. Smith MR, Egerdie B, Hernandez TN, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361(8):745-755
67. Fizazi K, Lipton A, Mariette X, et al. Randomized Phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27(10):1564-1571
68. Lewiecki Em NB. Assessing response to osteoporosis therapy. Osteoporos Int 2008;19(10):1363-1368